结膜结外边缘区淋巴瘤患者的长期结局
该单中心回顾性研究纳入72例原发性结膜结外边缘区淋巴瘤(PCEMZL)患者,中位年龄64岁,87.5%为I期,70.8%接受单纯放疗。中位随访6.7年,10年无进展生存(PFS)为68.4%,总生存(OS)为89.4%;MALT-IPI 0分与1-2分的10年PFS和OS分别为83.3% vs 51.3%和97.6% vs 76.6%。作者结论认为一线放疗患者长期生存极佳,MALT-IPI评分可识别治疗失败风险。
要点
- PCEMZL患者单纯放疗后完全缓解率达100%,全组完全缓解率为87.5%。
- 10年PFS为68.4%(95% CI 52.8%-79.8%),10年OS为89.4%(95% CI 77.4%-95.2%)。
- MALT-IPI 1-2分与0分相比,10年PFS为51.3% vs 83.3%(p=.022),10年OS为76.6% vs 97.6%(p=.0052)。
核心结论
- 接受一线放疗的PCEMZL患者表现出极佳的长期生存,MALT-IPI评分能适当识别治疗失败风险患者。
研究设计与样本
- 单中心回顾性研究,纳入72例原发性结膜结外边缘区淋巴瘤患者。
主要发现
- 中位年龄64岁,女性占63.9%,I期占87.5%,单纯放疗为最常见治疗(70.8%)。
- 全组完全缓解率为87.5%,放疗患者完全缓解率为100%。
- 中位随访6.7年,复发/进展和死亡各占19.4%,其中1例为放疗野内复发。
- 10年PFS为68.4%(95% CI 52.8%-79.8%),10年OS为89.4%(95% CI 77.4%-95.2%),10年至进展时间率为22.5%(95% CI 11.6%-35.7%)。
- MALT-IPI 0分 vs 1-2分的10年PFS为83.3% vs 51.3%(p=.022),10年OS为97.6% vs 76.6%(p=.0052)。
关键数值与推荐
- 年龄>60岁与较短PFS相关(HR=2.93,95% CI 1.08-7.95;p=.035)和较短OS相关(HR=9.07,95% CI 1.17-70.26;p=.035)。
- MALT-IPI 1-2分与较短PFS相关(HR=2.67,95% CI 1.12-6.31;p=.027)和较短OS相关(HR=6.64,95% CI 1.45-30.37;p=.015)。
- 一线治疗后完全缓解与较长PFS相关(HR=0.13,95% CI 0.04-0.45;p=.001),但与OS无显著关联。
- Fine and Gray竞争风险模型(以无复发/进展死亡为竞争风险)显示,放疗与较低复发风险相关(SHR=0.34,95% CI 0.12-0.96;p=.041),一线治疗后完全缓解与较低复发风险相关(SHR=0.11,95% CI 0.03-0.36;p<.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Comprehensive information on clinical features and long-term outcomes of primary conjunctival extranodal marginal zone lymphoma (PCEMZL) is scarce. We present a large single-institution retrospective study of 72 patients. The median age was 64 years, and 63.9% were female. Stage I was present in 87.5%. Radiation therapy (RT) alone was the most common treatment (70.8%). Complete response (CR) was 87.5%, and 100% in RT-treated patients. With a median follow-up of 6.7 years, relapse/progression and death occurred in 19.4% each, with one relapse within the RT field. The 10-year progression-free survival (PFS) and overall survival (OS) were 68.4% (95% CI 52.8%-79.8%) and 89.4% (95% CI 77.4%-95.2%), respectively. The 10-year rate for time to progression from diagnosis was 22.5% (95% CI 11.6%-35.7%). The 10-year PFS and OS of MALT-IPI 0 versus 1-2 were 83.3% versus 51.3%, (p = .022) and 97.6% versus 76.6%, (p = .0052), respectively. The following characteristics were associated with shorter survival: age > 60 years (PFS: HR = 2.93, 95% CI 1.08-7.95; p = .035, OS: HR = 9.07, 95% CI 1.17-70.26; p = .035) and MALT-IPI 1-2 (PFS: HR = 2.67, 95% CI 1.12-6.31; p = .027, OS: HR = 6.64, 95% CI 1.45-30.37; p = .015). CR following frontline therapy was associated with longer PFS (HR = 0.13, 95% CI 0.04-0.45; p = .001), but not OS. Using the Fine and Gray regression model with death without relapse/progression as a competing risk, RT and CR after frontline therapy were associated with lower risk of relapse (SHR = 0.34, 95% CI 0.12-0.96 p = .041 and SHR = 0.11, 95% CI 0.03-0.36; p < .001, respectively). Patients with PCEMZL treated with frontline RT exhibit excellent long-term survival, and the MALT-IPI score appropriately identifies patients at risk for treatment failure.
引用
- Saul EE, Alderuccio JP, Reis IM, et al. Long-term outcomes of patients with conjunctival extranodal marginal zone lymphoma. Am J Hematol. 2022. PMID: 35560252. doi:10.1002/ajh.26591
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。